Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Sales (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Return on Sales for 10 consecutive years, with 0.62% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 19.0% to 0.62% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.85%, a 16.0% increase, with the full-year FY2025 number at 0.85%, up 16.0% from a year prior.
  • Return on Sales was 0.62% for Q4 2025 at Ultragenyx Pharmaceutical, up from 1.13% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.62% in Q4 2025 to a low of 2.7% in Q3 2022.
  • A 5-year average of 1.32% and a median of 1.39% in 2021 define the central range for Return on Sales.
  • Biggest YoY gain for Return on Sales was 191bps in 2021; the steepest drop was -182bps in 2021.
  • Ultragenyx Pharmaceutical's Return on Sales stood at 1.5% in 2021, then grew by 2bps to 1.47% in 2022, then skyrocketed by 34bps to 0.97% in 2023, then rose by 16bps to 0.82% in 2024, then grew by 24bps to 0.62% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Return on Sales are 0.62% (Q4 2025), 1.13% (Q3 2025), and 0.69% (Q2 2025).